BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., today announced publication of new analysis demonstrating the cost-effectiveness of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). The analysis, published in the peer-reviewed journal Postgraduate Medicine, showed that reSET-O plus treatment-as-usual (TAU) (i.e., transmucosal buprenorphine, face-to-face counseling and contingency management) decreased total health care costs and resulted in improved post-treatment quality-adjusted life year (QALY) gains.

“OUD is one of the deadliest and costliest health conditions in the United States, generating close to 50,000 deaths and costing an estimated 40 to 70 billion dollars in annual medical costs each year, mostly from the more than 80% of untreated patients. Already high OUD-related deaths jumped after the start of

Read More At Article Source | Article Attribution